作者
Katherine H Thompson, Jay Lichter, Carl LeBel, Michael C Scaife, John H McNeill, Chris Orvig
发表日期
2009/4/1
来源
Journal of inorganic biochemistry
卷号
103
期号
4
页码范围
554-558
出版商
Elsevier
简介
3-Hydroxy-2-methyl-4-pyrone and 2-ethyl-3-hydroxy-4-pyrone (maltol and ethyl maltol, respectively) have proven especially suitable as ligands for vanadyl ions, in potential insulin enhancing agents for diabetes mellitus. Both bis(maltolato)oxovanadium(IV) (BMOV), and the ethylmaltol analog, bis(ethylmaltolato)oxovanadium(IV) (BEOV), have the desired intermediate stability for pro-drug use, and have undergone extensive pre-clinical testing for safety and efficacy. Pharmacokinetic evaluation indicates a pattern of biodistribution consistent with fairly rapid dissociation and uptake, binding to serum transferrin for systemic circulation and transport to tissues, with preferential uptake in bone. These bis-ligand oxovanadium(IV) (VOL2) compounds have a clear advantage over inorganic vanadyl sulfate in terms of bioavailability and pharmaceutical efficacy. BEOV has now completed Phase I and has advanced to Phase II …
引用总数
20092010201120122013201420152016201720182019202020212022202320249223941555452354442534034422719
学术搜索中的文章
KH Thompson, J Lichter, C LeBel, MC Scaife… - Journal of inorganic biochemistry, 2009